1/16
05:52 pm
ibrx
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]
Medium
Report
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]
1/16
02:23 pm
ibrx
Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]
Medium
Report
Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]
1/16
11:51 am
ibrx
ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]
Neutral
Report
ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]
1/16
09:34 am
ibrx
Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]
Low
Report
Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]
1/16
08:27 am
ibrx
ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]
Medium
Report
ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]
1/16
07:56 am
ibrx
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG [Yahoo! Finance]
Low
Report
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG [Yahoo! Finance]
1/16
07:50 am
ibrx
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more [CNBC]
Low
Report
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more [CNBC]
1/16
07:16 am
ibrx
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma [Yahoo! Finance]
Medium
Report
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma [Yahoo! Finance]
1/16
07:00 am
ibrx
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
High
Report
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
1/16
07:00 am
ibrx
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
High
Report
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
1/15
07:02 pm
ibrx
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year [Yahoo! Finance]
High
Report
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year [Yahoo! Finance]
1/15
06:00 pm
ibrx
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% [Yahoo! Finance]
High
Report
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% [Yahoo! Finance]
1/15
02:17 pm
ibrx
ImmunityBio: Why I Am Upgrading To A Buy For 2026 [Seeking Alpha]
Low
Report
ImmunityBio: Why I Am Upgrading To A Buy For 2026 [Seeking Alpha]
1/15
08:30 am
ibrx
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
High
Report
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
1/14
07:11 pm
ibrx
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ [Yahoo! Finance]
High
Report
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ [Yahoo! Finance]
1/14
03:01 pm
ibrx
Update: ImmunityBio Gets Approval From Saudi FDA For Non-Muscle Invasive Bladder Cancer Treatment; Shares Rise [Yahoo! Finance]
Low
Report
Update: ImmunityBio Gets Approval From Saudi FDA For Non-Muscle Invasive Bladder Cancer Treatment; Shares Rise [Yahoo! Finance]
1/14
02:21 pm
ibrx
H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment [Yahoo! Finance]
Low
Report
H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment [Yahoo! Finance]
1/14
09:22 am
ibrx
ImmunityBio announces results from Anktiva clinical program [Yahoo! Finance]
Low
Report
ImmunityBio announces results from Anktiva clinical program [Yahoo! Finance]
1/14
08:44 am
ibrx
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer [Yahoo! Finance]
Neutral
Report
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer [Yahoo! Finance]
1/14
08:30 am
ibrx
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Low
Report
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
1/14
08:30 am
ibrx
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
Low
Report
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
1/13
10:46 pm
ibrx
Assessing ImmunityBio (IBRX) Valuation After Positive ANKTIVA Lung Cancer Trial Results [Yahoo! Finance]
Medium
Report
Assessing ImmunityBio (IBRX) Valuation After Positive ANKTIVA Lung Cancer Trial Results [Yahoo! Finance]
1/13
03:21 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
1/13
08:57 am
ibrx
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer [Yahoo! Finance]
1/13
08:30 am
ibrx
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Medium
Report
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer